446eP PIV score as a predictor biomarker for survival in patients with extensive-stage SCLC treated with atezolizumab

20260 citationsJournal Articlegold Open Access

Authors

H.Z.E. Elsandoby · Western Health and Social Care Trust

R.R. Abdel Malek · Western Health and Social Care Trust

Abstract

The addition of Atezolizumab to platinum-based chemotherapy showed an improvement of the overall survival versus chemotherapy alone. However, studies focusing on predictive biomarkers to optimize patient selection and treatment strategies is needed. Therefore, our study aimed to evaluate the predictive impact for the pretreatment Pan-immune-inflammation value (PIV) score on survival outcomes in ES-SCLC.

Topics & Keywords

Lung Cancer Research Studies Neutropenia and Cancer Infections Cancer Immunotherapy and Biomarkers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: ESMO Open

Volume 11, pp. 106760-106760

DOI: 10.1016/j.esmoop.2026.106760

Field-Weighted Citation Impact: 0.00